VEGFR2 activity on myeloid cells mediates immune suppression in the tumor microenvironment

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

(2020) Richard S. Finn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma

(2020) Xu Yang† et al.   LANCET ONCOLOGY

PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade

(2020) Qi Peng et al.   Nature Communications

VCAM-1 Density and Tumor Perfusion Predict T-cell Infiltration and Treatment Response in Preclinical Models

(2019) Johannes Riegler et al.   NEOPLASIA

VEGF-A drives TOX-dependent T cell exhaustion in anti–PD-1–resistant microsatellite stable colorectal cancers

(2019) Chang Gon Kim et al.   Science Immunology

Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapy

(2019) Abhishek S. Kashyap et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Systematic Functional Annotation of Somatic Mutations in Cancer

(2018) Patrick Kwok-Shing Ng et al.   CANCER CELL

PD-L1 on host cells is essential for PD-L1 blockade–mediated tumor regression

(2018) Haidong Tang et al.   JOURNAL OF CLINICAL INVESTIGATION

IFNAR1 Controls Autocrine Type I IFN Regulation of PD-L1 Expression in Myeloid-Derived Suppressor Cells

(2018) Wei Xiao et al.   JOURNAL OF IMMUNOLOGY

Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges

(2018) Dai Fukumura et al.   Nature Reviews Clinical Oncology

Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa

(2018) Kabir A. Khan et al.   Nature Reviews Clinical Oncology

Improved Multiplex Immunohistochemistry for Immune Microenvironment Evaluation of Mouse Formalin-Fixed, Paraffin-Embedded Tissues

(2018) Noah Sorrelle et al.   JOURNAL OF IMMUNOLOGY

Cyclooxygenase-2 inhibition potentiates the efficacy of vascular endothelial growth factor blockade and promotes an immune stimulatory microenvironment in preclinical models of pancreatic cancer

(2018) Yuqing Zhang et al.   MOLECULAR CANCER RESEARCH

A proangiogenic signaling axis in myeloid cells promotes malignant progression of glioma

(2017) Yujie Huang et al.   JOURNAL OF CLINICAL INVESTIGATION

Development of conventional dendritic cells: from common bone marrow progenitors to multiple subsets in peripheral tissues

(2017) D Sichien et al.   Mucosal Immunology

Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade

(2017) Martina Schmittnaegel et al.   Science Translational Medicine

Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation

(2017) Elizabeth Allen et al.   Science Translational Medicine

The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition

(2016) P. S. Hegde et al.   CLINICAL CANCER RESEARCH

Expression of Vascular Endothelial Growth Factor in Ovarian Cancer Inhibits Tumor Immunity through the Accumulation of Myeloid-Derived Suppressor Cells

(2016) Naoki Horikawa et al.   CLINICAL CANCER RESEARCH

Expression Profiling of Macrophages Reveals Multiple Populations with Distinct Biological Roles in an Immunocompetent Orthotopic Model of Lung Cancer

(2016) Joanna M. Poczobutt et al.   JOURNAL OF IMMUNOLOGY

VEGF Neutralization Plus CTLA-4 Blockade Alters Soluble and Cellular Factors Associated with Enhancing Lymphocyte Infiltration and Humoral Recognition in Melanoma

(2016) X. Wu et al.   Cancer Immunology Research

VEGF-A modulates expression of inhibitory checkpoints on CD8+T cells in tumors

(2015) Thibault Voron et al.   JOURNAL OF EXPERIMENTAL MEDICINE

FLT1 signaling in metastasis-associated macrophages activates an inflammatory signature that promotes breast cancer metastasis

(2015) Bin-Zhi Qian et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Combined VEGF and CXCR4 antagonism targets the GBM stem cell population and synergistically improves survival in an intracranial mouse model of glioblastoma

(2015) Amy Barone et al.   Oncotarget

Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors

(2014) Gregory T Motz et al.   NATURE MEDICINE

Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma

(2014) F. S. Hodi et al.   Cancer Immunology Research

Collagen Signaling Enhances Tumor Progression after Anti-VEGF Therapy in a Murine Model of Pancreatic Ductal Adenocarcinoma

(2013) K. Y. Aguilera et al.   CANCER RESEARCH

Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer

(2013) Jonathan Welti et al.   JOURNAL OF CLINICAL INVESTIGATION

The miR-126–VEGFR2 axis controls the innate response to pathogen-associated nucleic acids

(2013) Judith Agudo et al.   NATURE IMMUNOLOGY

VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2

(2012) N G Gavalas et al.   BRITISH JOURNAL OF CANCER

VEGFA-VEGFR Pathway Blockade Inhibits Tumor-Induced Regulatory T-cell Proliferation in Colorectal Cancer

(2012) M. Terme et al.   CANCER RESEARCH

Active Immunotherapy Combined With Blockade of a Coinhibitory Pathway Achieves Regression of Large Tumor Masses in Cancer-prone Mice

(2011) Marcio O Lasaro et al.   MOLECULAR THERAPY

Molecular mechanisms and clinical applications of angiogenesis

(2011) Peter Carmeliet et al.   NATURE

r84, a Novel Therapeutic Antibody against Mouse and Human VEGF with Potent Anti-Tumor Activity and Limited Toxicity Induction

(2010) Laura A. Sullivan et al.   PLoS One

Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis

(2009) Marta Pàez-Ribes et al.   CANCER CELL

Cytokine Levels Correlate with Immune Cell Infiltration after Anti-VEGF Therapy in Preclinical Mouse Models of Breast Cancer

(2009) Christina L. Roland et al.   PLoS One

Vascular Endothelial Growth Factor Receptor 2 Mediates Macrophage Infiltration into Orthotopic Pancreatic Tumors in Mice

(2008) S. P. Dineen et al.   CANCER RESEARCH